Asymptomatic MGD more common than symptomatic

Article

A symptom-based approach may lead to an underestimation of MGD prevalence

"The high proportion of asymptomatic patients should alert us to the possibility of unnoticed progression of meibomian gland dysfunction (MGD)," emphasized Dr Eloy Viso (Servico de Oftalmología, Complexo Hospitalario de Pontevedra, Pontevedra, Spain) when discussing the results of a recent study on a general Spanish adult population.

The study

A population-based approach was used to obtain a representative sample of the population noted Dr Viso. The possibility of selection bias was also evaluated to ensure the results were fair. "We used a stratified sampling procedure so a representative sample could be obtained in each age group and we performed a design based analysis to account for the stratified sampling and the unequal probability selection," added Dr Viso. "With respect to diagnostic criteria, which are an important cause of variability between studies, we included signs of the 2 categories described in the new MGD classification to reduce the number of false negatives and removed indirect indicators to reduce the number of false positives."

Additionally, a standardized symptoms questionnaire was employed. "We used the questionnaire developed by Schein et al.1 because it was the most widely used in population-based studies and because it included symptoms such as eyes stuck shut that have been considered, in spite of a lack of sufficient evidence, more characteristic of MGD," he continued. "The biomicroscopic examination of the ocular surface, however, was performed without knowledge of the results of the questionnaire."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.